immunoINSIGHTS 2K™
Unlocking the hidden intelligence of the human immune system for Biopharma & Research
Next-generation autoantibody profiling
The immunoINSIGHTS 2K platform from Oncimmune delivers an integrated, standardized, and AI-enhanced approach to immune-system intelligence, leveraging Alden Scientific’s health and disease multi-modal models. This approach enables scientists, clinicians, and drug developers to understand immune activity with unprecedented confidence and comparability.
immunoINSIGHTS 2K is an integrated and standardized autoantibody profiling platform that unites four unique core elements:
2K Clinically Translatable Antigens
A verified panel of 1,920 human-disease-relevant antigens generated from over 30,000 clinical samples
Population Data Warehouse
The largest reference data set of 10,000+ immune profiles across diseases and demographics
Comparison Engine
The ability to benchmark and contextualize your data against this large-scale population dataset
Alden Scientific’s signalINTELLIGENCE™ AI
Advanced analytics that uncover patterns, signatures, and predictive biomarkers across datasets
Together, these components form a single ecosystem for reliable, comparable, and insight-rich immune profiling. Bespoke additional antigens can also be added, including post-translational modifications of antigens.
Autoantibodies remain one of the most under-explored dimensions of human biology.
They often emerge years before clinical disease – across cancer, autoimmune disorders, infection, and aging. By analyzing these early signals at population scale, immunoINSIGHTS 2K enables:
Early detection and risk stratification across diverse diseases
Precise disease subtyping and patient segmentation for clinical and translational programs
Discovery of novel targets and biological pathways
Replication and validation of biomarkers across studies, overcoming the lack of statistical power seen in many trials
Exclusive benefits for early collaboration partners:
Priority access to the first 10,000-sample dataset from the largest autoantibody-profiling initiative ever conducted
Opportunity to join the founding Expert Panel to help guide research protocols and platform development
Exclusive collaboration with Alden Scientific’s AI and biomarker discovery teams
Signal Intelligence data interpretation — complimentary during the launch phase
Co-development and copublication opportunities with Oncimmune and Alden Scientific
Limited time to benefit from these exclusive benefits: eligible groups include biopharma translational and biomarker teams
Framework: joint project agreements with defined datasharing protocols and secure result delivery
From isolated antibody signals, immunoINSIGHTS 2K identifies immune signatures that reveal how diseases originate, evolve, and respond to therapy.
Only platform that merges clinicalgrade autoantibody arrays, crosspopulation data benchmarking, and AI-powered immune intelligence
Designed for regulatory-ready translational programs with reproducibility and data transparency at its core
Offers seamless cross-analysis with Olink and other proteomic platforms, expanding the interpretive reach of every dataset
Available Today
Assays are available in serum, plasma, saliva, and CSF.
Supplementary information and platform architecture
Over the past decade, Oncimmune’s Luminex® bead-based platform has analyzed more than 30,000 patient samples generating reproducible, high-precision immune data. This has supported over 25 drug development programs, of which 7 drugs are approved. From accelerating FDA approval for a top pharma, to demonstrating prediction of cytokinerelease syndrome and immune-response to a BTK inhibitor, we support clinical development from phase I to III.
The integration with Alden Scientific now extends this expertise from assay excellence to large-scale data interpretation. Using AI-driven analytics, immunoINSIGHTS 2K connects clinical-grade antibody signals with biological meaning—providing population-level benchmarks and predictive insights unavailable through traditional methods.
Pharma partners increasingly demand robust, standardized immune-profiling data to accelerate translational and regulatory decision-making, however clinical trials are rarely powered for biomarker discovery and verification of results. Translation of biomarker signals into clinically actionable tests is a major challenge and requires population-size studies. immunoINSIGHTS 2K directly addresses this need by combining assay precision, biological depth, and analytical scalability, along with background antibody profiles in a population that can provide immediate verification of clinical relevance - all this in a single framework.
Core Assay Technology
Luminex bead-based multiplexed immunoassay optimized for sensitivity, specificity, and reproducibility
Antigen Library
1,920 antigens - 100 validated gold standards + 1,820 disease-relevant proteins curated from autoimmune, oncology, infection, neurology, and allergy research, and generated from a >200,000 ORF library
Al Analytics
Alden's signalINTELLIGENCE platform contextualizes every result within the growing immune-data warehouse of 10,000 profiles
Cross-Platform Integration
Comparative analysis against Olink panels containing an over 600 protein overlap for multi-omic validation
Data Security
De-identified, GDPR compliant data handling; ISO 9001 laboratory standards
Partner With Alden
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat.
Partner With Alden